Money
Filter News
Found 61,371 articles
-
In a filing with the U.S. Securities and Exchange Commission, Johnson & Johnson said it will abandon development of AL-8176, one of the assets it acquired in the Alios deal.
-
Alcon will officially step out from under the Novartis umbrella on April 9 as it will trade on the NYSE and the SIX Swiss Exchange.
-
Cardea Bio Announces $7.8 Million Series A-1 Financing
3/22/2019
Financing to support the growth of the company’s graphene-based digital biosensor infrastructure, driving novel applications through new Innovation Partnership Program
-
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
3/22/2019
AgeX Therapeutics, Inc., a biotechnology company focused on innovative therapeutics for human aging, announced that it has received $4.5 million from the exercise of AgeX common stock warrants.
-
Evox Therapeutics Awarded £1.5 Million in Funding From Innovate UK
3/22/2019
Proceeds will support advancement of an exosome therapy to treat a urea cycle disorder
-
Perhaps the last big hope for a successful Alzheimer’s drug just died. Biogen and its collaboration partner, Eisai, announced they were discontinuing the global Phase III clinical trials of aducanumab in patients with mild cognitive impairment from Alzheimer’s.
-
Exscientia will use its full-stack AI drug discovery platform, Centaur Chemist, to accelerate the discovery of small molecule therapeutic drug candidates. It will focus on three of Celgene’s therapeutic programs in oncology and autoimmunity.
-
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
-
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
-
Rite Aid Stockholders Approve Reverse Stock Split
3/21/2019
Rite Aid Corporation (NYSE: RAD) announced that its stockholders approved a reverse stock split of the company’s common stock at today’s Special Meeting of Stockholders. According to preliminary tabulations, with approximately 987 million eligible votes cast, stockholders voted 78% in favor of the reverse split.
-
Sasol Offers Support to Cyclone Idai Victims
3/21/2019
Sasol committed to donate US$250,000, approximately 15 million meticais, for the relief and support of communities that have been severely affected by tropical Cyclone Idai in Beira and Dondo in Sofala province, as well as other impacted areas in Inhambane province, Mozambique.
-
Investment in Midwest Healthcare Companies Remains Steady at $2.5 Billion in 2018, Validating Record Increase of 43% in 2017
3/21/2019
Investment in Midwest healthcare companies remained steady in 2018, with $2.5 billion in capital raised by 438 companies
-
Lannett Purchases $24 Million Of Term Loans In Open Market Transactions
3/21/2019
Lannett Company, Inc. announced that it completed the purchase of approximately $24.2 million principal amount of its Term Loans in open market transactions.
-
Imago BioSciences Announces $40 Million Series B Financing Led by Omega Funds
3/21/2019
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds, a leading international investment firm that creates and invests in life sciences companies.
-
EQT Foundation Announces Record Charitable Giving in 2018
3/21/2019
Residents, Communities and Organizations Throughout EQT’s Operating Areas Benefit from the Foundation’s Strong Support
-
HENRY The Dentist Raises $10 Million To Expand Its Fleet Of Mobile Dental Practices
3/21/2019
HENRY The Dentist announced the closing of a $10 million Series A financing, led by Forerunner Ventures, to expand its fleet of mobile dental practices to companies in New Jersey, Pennsylvania, Georgia, New York and additional states across the US.
-
BioPharmX Announces $3.9 Million Offering
3/21/2019
BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering.
-
Cellular Biomedicine Group Announces Pricing of Public Offering of Common Stock
3/21/2019
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the pricing of an underwritten public offering of 1,029,412 shares of its common stock at a public offering price of $17.00 per share.
-
AbbVie Donates $40 Million to Rebuild North Chicago Middle School
3/21/2019
Rebuilding Neal Math & Science Academy supports student success and underscores AbbVie's ongoing commitment to North Chicago, where the company is headquartered
-
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
3/21/2019
ZULRESSO is the first and only treatment specifically indicated for postpartum depression